School of Medicine

Publications

• Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes.
  Bulek AM, Cole DK, Skowera A, Dolton G, Gras S, Madura F, Fuller A, Miles JJ, Gostick E, Price DA, Drijfhout JW, Knight RR, Huang GC, Lissin N, Molloy PE, Wooldridge L, Jakobsen BK, Rossjohn J, Peakman M, Rizkallah PJ, Sewell AK, Nat Immunol, Volume 13, 3 (March 2012) pp.283-289
• A single autoimmune T cell receptor recognizes more than a million different peptides.
  Wooldridge L, Ekeruche-Makinde J, van den Berg HA, Skowera A, Miles JJ, Tan MP, Dolton G, Clement M, Llewellyn-Lacey S, Price DA, Peakman M, Sewell AK, J Biol Chem, Volume 287, 2 (January 2012) pp.1168-1177
• Co-operative membrane disruption between cell-penetrating peptide and cargo: implications for the therapeutic use of the Bcl-2 converter peptide D-NuBCP-9-r8.
  Watkins CL, Sayers EJ, Allender C, Barrow D, Fegan C, Brennan P, Jones AT, Mol Ther, Volume 19, 12 (December 2011) pp.2124-2132
• Failure to detect production of IL-10 by activated human neutrophils
  Davey MS, Tamassia N, Rossato M, Bazzoni F, Calzetti F, Bruderek K, Sironi M, Zimmer L, Bottazzi B, Mantovani A, Brandau S, Moser B, Eberl M, Cassatella MA, Nature Immunol, Volume 12, 11 (November 2011) pp.1017-1018
• Two novel aspirin analogues show selective cytotoxicity in primary chronic lymphocytic leukaemia cells that is associated with dual inhibition of Rel A and COX-2.
  Pepper C, Mahdi JG, Buggins AG, Hewamana S, Walsby E, Mahdi E, Al-Haza'a A, Mahdi AJ, Lin TT, Pearce L, Morgan L, Bowen ID, Brennan P, Fegan C, Cell Prolif, Volume 44, 4 (August 2011) pp.380-390

• More Immunotherapy publications